Junichi Shimamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Junichi Shimamura has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
David Spielvogel
Division of Cardiothoracic Surgery, Department of Surgery Westchester Medical Center Valhalla New York USA
6 shared publications- Suguru Ohira
Department of Cardiac Surgery, Hartford Hospital, Hartford, CT, USA
6 shared publications - Toshiki Kuno
Harvard Medical School
6 shared publications - Hisato Takagi
Shizuoka medical center, Shizuoka, Japan
5 shared publications Eisuke Tatsumi
Department of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
4 shared publications- Hiroshi Kubota
Department of Cardiovascular Surgery, Kyorin University
4 shared publications
Latest Publications
- 13 August 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (11) , 1668-1671
276 Days of Support by a Micro‐Axial Left Ventricular Assist Device as a Bridge to Heart Transplant
The Impella 5.5 is a surgically implanted micro‐axial left ventricular assist device (LVAD) increasingly utilized for mechanical circulatory support (MCS) in cardiogenic shock. While typically used for acute support up to FDA‐approved 14 days, reports of prolonged utilization remain limited. We present the case of a 69‐year‐old male who presented with severe biventricular failure and cardiogenic shock who was bridged to heart transplantation (HT) utilizing a single Impella 5.5 for a total of 276 days. His prolonged support course was managed through a multidisciplinary approach addressing recurrent ventricular arrhythmias, renal failure, heparin‐induced thrombocytopenia, and device management (suction alarms and purge flow limitations). Following successful HT, the explanted device demonstrated no mechanical injury or thrombus, and pathologic examination revealed no significant device‐related structural heart damage. The patient was discharged without major complications and continued to do well at 5‐month follow‐up.
- 13 August 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (11) , 1668-1671
276 Days of Support by a Micro‐Axial Left Ventricular Assist Device as a Bridge to Heart Transplant
The Impella 5.5 is a surgically implanted micro‐axial left ventricular assist device (LVAD) increasingly utilized for mechanical circulatory support (MCS) in cardiogenic shock. While typically used for acute support up to FDA‐approved 14 days, reports of prolonged utilization remain limited. We present the case of a 69‐year‐old male who presented with severe biventricular failure and cardiogenic shock who was bridged to heart transplantation (HT) utilizing a single Impella 5.5 for a total of 276 days. His prolonged support course was managed through a multidisciplinary approach addressing recurrent ventricular arrhythmias, renal failure, heparin‐induced thrombocytopenia, and device management (suction alarms and purge flow limitations). Following successful HT, the explanted device demonstrated no mechanical injury or thrombus, and pathologic examination revealed no significant device‐related structural heart damage. The patient was discharged without major complications and continued to do well at 5‐month follow‐up.
- Open Access
- 9 April 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 38
Use of Microaxial Left Ventricular Assist Device in Patients with Severe Aortic Insufficiency and Cardiogenic Shock
- 9 April 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 38
Open AccessUse of Microaxial Left Ventricular Assist Device in Patients with Severe Aortic Insufficiency and Cardiogenic Shock
- Open Access
- 26 February 2026
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (3) , 102193
May-Thurner syndrome disguised as pulmonary embolism: A case report
- 26 February 2026
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (3) , 102193
Open AccessMay-Thurner syndrome disguised as pulmonary embolism: A case report
- Open Access
- 18 September 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (10) , e1853
Simultaneous Heart and Kidney Transplantation Using Circulatory Death Donors: Are Kidney Graft Outcomes Comparable With Brain Death Donors?
Background.: There is limited evidence on heart and kidney transplants using donation after circulatory death (DCD) donors, especially regarding graft outcomes. However, little is known about the use of DCD donors for simultaneous heart and kidney transplants (SHKTs) compared with SHKTs using donation after brain death (DBD) donors. Methods.: From May 22, 2020, to September 30, 2023, 1129 adult patients received SHKTs (DCD, N = 91 versus DBD, N = 1038), identified using the United Network for Organ Sharing database, excluding other multiorgan transplants and retransplants. A propensity score matching was performed using characteristics. Ninety-one DCD- and 273 DBD-matched cases were compared. Results.: In the unmatched cohort, DCD recipients were older (DCD: 60 versus DBD: 58 y, P = 0.03), had a lower rate of dialysis at transplant (27% versus 40%, P = 0.03), and were of status 1 to 2 (43% versus 72%, P < 0.001). In the matched cohort, kidney delayed graft function (27% versus 22%, P = 0.29) was comparable, as were recipient survival (P = 0.19), heart graft survival (P = 0.19), and kidney graft survival (P = 0.17). In multivariate Cox proportional hazards analysis, donor type (DCD) was not associated with an increased risk of mortality (hazard ratio, 1.69; 95% confidence interval, 0.90-3.16; P = 0.10). Subgroup analysis showed that survival and freedom from graft failures were comparable between different modes of DCD recovery. Conclusions.: SHKT using DCD donors yields comparable survival and graft outcomes to those using DBD donors. These findings may help donor selection in heart transplant candidates with kidney dysfunction.
- 18 September 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (10) , e1853
Open AccessSimultaneous Heart and Kidney Transplantation Using Circulatory Death Donors: Are Kidney Graft Outcomes Comparable With Brain Death Donors?
Background.: There is limited evidence on heart and kidney transplants using donation after circulatory death (DCD) donors, especially regarding graft outcomes. However, little is known about the use of DCD donors for simultaneous heart and kidney transplants (SHKTs) compared with SHKTs using donation after brain death (DBD) donors. Methods.: From May 22, 2020, to September 30, 2023, 1129 adult patients received SHKTs (DCD, N = 91 versus DBD, N = 1038), identified using the United Network for Organ Sharing database, excluding other multiorgan transplants and retransplants. A propensity score matching was performed using characteristics. Ninety-one DCD- and 273 DBD-matched cases were compared. Results.: In the unmatched cohort, DCD recipients were older (DCD: 60 versus DBD: 58 y, P = 0.03), had a lower rate of dialysis at transplant (27% versus 40%, P = 0.03), and were of status 1 to 2 (43% versus 72%, P < 0.001). In the matched cohort, kidney delayed graft function (27% versus 22%, P = 0.29) was comparable, as were recipient survival (P = 0.19), heart graft survival (P = 0.19), and kidney graft survival (P = 0.17). In multivariate Cox proportional hazards analysis, donor type (DCD) was not associated with an increased risk of mortality (hazard ratio, 1.69; 95% confidence interval, 0.90-3.16; P = 0.10). Subgroup analysis showed that survival and freedom from graft failures were comparable between different modes of DCD recovery. Conclusions.: SHKT using DCD donors yields comparable survival and graft outcomes to those using DBD donors. These findings may help donor selection in heart transplant candidates with kidney dysfunction.
- Open Access
- 5 March 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (5) , 103084
Transcatheter Vacuum-Assisted Mass Extraction on a Mitral Bioprosthesis
- 5 March 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (5) , 103084
Open AccessTranscatheter Vacuum-Assisted Mass Extraction on a Mitral Bioprosthesis
- Open Access
- 5 February 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (2)
Implantation of a temporary microaxial left ventricular assist device via the right axillary artery in a patient with aberrant right subclavian artery
A temporary microaxial left ventricular assist device is commonly implanted via the right axillary artery to treat decompensated heart failure or cardiogenic shock. However, limited literature describes implantation in a variant aortic arch anatomy setting. We present a case of implantation via the right axillary artery in a patient with an aberrant right subclavian artery (Arteria Lusoria) as a bridge to heart transplantation.
- 5 February 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (2)
Open AccessImplantation of a temporary microaxial left ventricular assist device via the right axillary artery in a patient with aberrant right subclavian artery
A temporary microaxial left ventricular assist device is commonly implanted via the right axillary artery to treat decompensated heart failure or cardiogenic shock. However, limited literature describes implantation in a variant aortic arch anatomy setting. We present a case of implantation via the right axillary artery in a patient with an aberrant right subclavian artery (Arteria Lusoria) as a bridge to heart transplantation.
- Open Access
- 1 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (10) , ytae518
Pannus formation: a rare culprit of early bioprosthetic valve dysfunction—a case report
Background: Early bioprosthetic valve dysfunction (BVD) due to pannus formation is uncommon in elderly patients, and only a limited number of cases have been reported. Case summary: An 84-year-old man presented with exertional dyspnoea 3 years after surgical aortic valve replacement (SAVR) with a 19 mm Epic™ valve (Abbott, Santa Clara, CA, USA). Transthoracic echocardiography demonstrated progressive BVD, and cardiac computed tomography (CT) revealed sub-aortic pannus formation. Re-operative SAVR was performed using a 19 mm INSPIRIS RESILIA® valve (Edwards Lifesciences, Irvine, CA, USA), and pathological examination confirmed valve leaflet deformation caused by pannus overgrowth. At the 18-month follow-up, the patient exhibited favourable progress, with no indications of BVD or pannus recurrence. Discussion: This case highlights the importance of recognizing early pannus formation as a cause of BVD, even in elderly patients. Early detection of BVD based on clinical symptoms and echocardiography is vital to allow timely surgical intervention before the deterioration of cardiac function. Cardiac CT helps to differentiate pannus from thrombus formation and guide treatment decisions.
- 1 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 8 (10) , ytae518
Open AccessPannus formation: a rare culprit of early bioprosthetic valve dysfunction—a case report
Background: Early bioprosthetic valve dysfunction (BVD) due to pannus formation is uncommon in elderly patients, and only a limited number of cases have been reported. Case summary: An 84-year-old man presented with exertional dyspnoea 3 years after surgical aortic valve replacement (SAVR) with a 19 mm Epic™ valve (Abbott, Santa Clara, CA, USA). Transthoracic echocardiography demonstrated progressive BVD, and cardiac computed tomography (CT) revealed sub-aortic pannus formation. Re-operative SAVR was performed using a 19 mm INSPIRIS RESILIA® valve (Edwards Lifesciences, Irvine, CA, USA), and pathological examination confirmed valve leaflet deformation caused by pannus overgrowth. At the 18-month follow-up, the patient exhibited favourable progress, with no indications of BVD or pannus recurrence. Discussion: This case highlights the importance of recognizing early pannus formation as a cause of BVD, even in elderly patients. Early detection of BVD based on clinical symptoms and echocardiography is vital to allow timely surgical intervention before the deterioration of cardiac function. Cardiac CT helps to differentiate pannus from thrombus formation and guide treatment decisions.
- 2 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15451
Strategy and Outcomes of Cardiac Surgery in Patients With Cirrhosis: Comprehensive Approach With Liver Transplant Program
Background: Cardiac surgery is considered a contraindication in patients with advanced liver cirrhosis (LC) due to increased mortality and morbidity. There are limited data on the treatment strategy and management of this population. We aimed to present our strategy and evaluate the clinical outcome of cardiac surgery in patients with LC.Methods: Our strategy was (i) to list patients for liver transplant (LT) at the time of cardiac surgery; (ii) to maintain high cardiopulmonary bypass (CPB) flow (index up to 3.0 L/min/m2) based on hyper‐dynamic states due to LC; and (iii) to proceed to LT if patients’ liver function deteriorated with an increasing model for end‐stage liver disease Na (MELD‐Na) score after cardiac surgery. Thirteen patients (12 male and 1 female [mean age, 63.0]) with LC who underwent cardiac surgery between 2017 and 2024 were retrospectively analyzed.Results: Six patients were listed for LT. Indications for cardiac surgery included coronary artery disease (N = 7), endocarditis (N = 2), and tricuspid regurgitation (N = 1), tricuspid stenosis (N = 1), mitral regurgitation (N = 1), and hypertrophic obstructive cardiomyopathy (N = 1). The Child–Pugh score was A in five, B in six, and C in one patient. The procedure included coronary artery bypass grafting (N = 6), single valve surgery (mitral valve [N = 2] and tricuspid valve [N = 1]), concomitant aortic and tricuspid valve surgery (N = 2), and septal myectomy (N = 1). Two patients had a history of previous sternotomy. The perfusion index during CPB was 3.1 ± 0.5 L/min/m2. Postoperative complications include pleural effusion (N = 6), bleeding events (N = 3), acute kidney injury (N = 1), respiratory failure requiring tracheostomy (N = 2), tamponade (N = 1), and sternal infection (N = 1). There was no in‐hospital death. There was one remote death due to COVID‐19 complication. Preoperative and postoperative highest MELD‐Na score among listed patients was 15.8 ± 5.1 and 19.3 ± 5.3, respectively. Five patients underwent LT (1, 5, 8, 16, and 24 months following cardiac surgery) and one patient remains on the list. Survival rates at 1 and 3 years are 100% and 75.0%, respectively.Conclusion: Cardiac surgery maintaining high CPB flow with LT backup is a feasible strategy in an otherwise inoperable patient population with an acceptable early and midterm survival when performed in a center with an experienced cardiac surgery and LT program.
- 2 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15451
Strategy and Outcomes of Cardiac Surgery in Patients With Cirrhosis: Comprehensive Approach With Liver Transplant Program
Background: Cardiac surgery is considered a contraindication in patients with advanced liver cirrhosis (LC) due to increased mortality and morbidity. There are limited data on the treatment strategy and management of this population. We aimed to present our strategy and evaluate the clinical outcome of cardiac surgery in patients with LC.Methods: Our strategy was (i) to list patients for liver transplant (LT) at the time of cardiac surgery; (ii) to maintain high cardiopulmonary bypass (CPB) flow (index up to 3.0 L/min/m2) based on hyper‐dynamic states due to LC; and (iii) to proceed to LT if patients’ liver function deteriorated with an increasing model for end‐stage liver disease Na (MELD‐Na) score after cardiac surgery. Thirteen patients (12 male and 1 female [mean age, 63.0]) with LC who underwent cardiac surgery between 2017 and 2024 were retrospectively analyzed.Results: Six patients were listed for LT. Indications for cardiac surgery included coronary artery disease (N = 7), endocarditis (N = 2), and tricuspid regurgitation (N = 1), tricuspid stenosis (N = 1), mitral regurgitation (N = 1), and hypertrophic obstructive cardiomyopathy (N = 1). The Child–Pugh score was A in five, B in six, and C in one patient. The procedure included coronary artery bypass grafting (N = 6), single valve surgery (mitral valve [N = 2] and tricuspid valve [N = 1]), concomitant aortic and tricuspid valve surgery (N = 2), and septal myectomy (N = 1). Two patients had a history of previous sternotomy. The perfusion index during CPB was 3.1 ± 0.5 L/min/m2. Postoperative complications include pleural effusion (N = 6), bleeding events (N = 3), acute kidney injury (N = 1), respiratory failure requiring tracheostomy (N = 2), tamponade (N = 1), and sternal infection (N = 1). There was no in‐hospital death. There was one remote death due to COVID‐19 complication. Preoperative and postoperative highest MELD‐Na score among listed patients was 15.8 ± 5.1 and 19.3 ± 5.3, respectively. Five patients underwent LT (1, 5, 8, 16, and 24 months following cardiac surgery) and one patient remains on the list. Survival rates at 1 and 3 years are 100% and 75.0%, respectively.Conclusion: Cardiac surgery maintaining high CPB flow with LT backup is a feasible strategy in an otherwise inoperable patient population with an acceptable early and midterm survival when performed in a center with an experienced cardiac surgery and LT program.
- Open Access
Simultaneous Heart and Kidney Transplantation utilizing Circulatory Death Donors in the United States
Objective Heart transplants utilizing donors from circulatory death (DCD) allografts are rapidly growing with the potential to expand the donor pool. However, little is known about the use of DCD donors for simultaneous heart and kidney transplants (SHKT) compared to SHKT using brain death donors (DBD). Methods From May 22, 2020, to September 30, 2023, 1,129 adult patients received SHKT (DCD, N=91 vs. DBD, N=1,038), identified using the United Network for Organ Sharing database, excluding other multi-organ transplants and re-transplants. A 1:3 ratio propensity score matching was performed using 17 recipient characteristics and 7 donor characteristics. A total of 91 DCD and 273 DBD matched cases were compared. Results In the unmatched cohort, DCD recipients were older (DCD: 60 vs. DBD: 58 years, p=0.03) and had a lower rate of dialysis at transplant (27% vs. 40%, p=0.03) and status 1 to 2 patients (43% vs. 72%, p<.001). Donors were younger (30 vs. 32 years, p=0.02) in the DCD group. In the matched cohort, kidney delayed graft function (27% vs. 22%, p=0.29) was comparable, as were recipient survival (p=0.19), heart graft survival (p=0.19), and kidney graft survival (p=0.17). In multivariate Cox proportional hazards analysis, donor type (DCD) was not associated with an increased risk of mortality (HR=1.69, 95% Cl 0.90-3.16, p=0.10). Sub-group analysis showed that survival and freedom from graft failures were comparable between different modes of DCD recovery. The centers performing both DCD- and DBD-SHKT showed significantly shorter waitlist days with comparable transplant outcomes compared to centers that only performed DBD-SHKT. Conclusions SHKT using DCD donors yields comparable survival and graft outcomes to those using DBD donors. These findings will guide treatment strategies for heart transplant candidates with kidney dysfunction, including the selection of donors and patients and safety net policy options.
Open AccessSimultaneous Heart and Kidney Transplantation utilizing Circulatory Death Donors in the United States
Objective Heart transplants utilizing donors from circulatory death (DCD) allografts are rapidly growing with the potential to expand the donor pool. However, little is known about the use of DCD donors for simultaneous heart and kidney transplants (SHKT) compared to SHKT using brain death donors (DBD). Methods From May 22, 2020, to September 30, 2023, 1,129 adult patients received SHKT (DCD, N=91 vs. DBD, N=1,038), identified using the United Network for Organ Sharing database, excluding other multi-organ transplants and re-transplants. A 1:3 ratio propensity score matching was performed using 17 recipient characteristics and 7 donor characteristics. A total of 91 DCD and 273 DBD matched cases were compared. Results In the unmatched cohort, DCD recipients were older (DCD: 60 vs. DBD: 58 years, p=0.03) and had a lower rate of dialysis at transplant (27% vs. 40%, p=0.03) and status 1 to 2 patients (43% vs. 72%, p<.001). Donors were younger (30 vs. 32 years, p=0.02) in the DCD group. In the matched cohort, kidney delayed graft function (27% vs. 22%, p=0.29) was comparable, as were recipient survival (p=0.19), heart graft survival (p=0.19), and kidney graft survival (p=0.17). In multivariate Cox proportional hazards analysis, donor type (DCD) was not associated with an increased risk of mortality (HR=1.69, 95% Cl 0.90-3.16, p=0.10). Sub-group analysis showed that survival and freedom from graft failures were comparable between different modes of DCD recovery. The centers performing both DCD- and DBD-SHKT showed significantly shorter waitlist days with comparable transplant outcomes compared to centers that only performed DBD-SHKT. Conclusions SHKT using DCD donors yields comparable survival and graft outcomes to those using DBD donors. These findings will guide treatment strategies for heart transplant candidates with kidney dysfunction, including the selection of donors and patients and safety net policy options.